Alzinova
Sweden - MölndalBiotechnology
Focus: Alzinova is a Swedish biotech company focused on developing an Alzheimer's vaccine and leveraging monoclonal antibody technology to address neurodegenerative diseases. The company is publicly listed and operates at an early clinical stage.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Alzinova
AI assessmentNot HiringNo open roles listed right now. Follow Alzinova to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
ALZ-101
Alzheimer DiseaseClinical Trials (1)
NCT05328115A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
Phase 1Help build intelligence for Alzinova
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.